Phreesia (NYSE:PHR) Given New $22.00 Price Target at Canaccord Genuity Group

Phreesia (NYSE:PHR) had its price target trimmed by Canaccord Genuity Group from $33.00 to $22.00 in a report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities analysts have also commented on the stock. Needham & Company LLC dropped their price target on shares of Phreesia from $35.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday. Royal Bank Of Canada began coverage on shares of Phreesia in a report on Friday, January 9th. They set a “moderate buy” rating and a $26.00 price objective for the company. Truist Financial reiterated a “hold” rating and issued a $11.00 target price (down from $24.00) on shares of Phreesia in a research note on Tuesday. Wall Street Zen downgraded shares of Phreesia from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 8th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $16.00 target price (down from $24.00) on shares of Phreesia in a research report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $22.00.

Phreesia Stock Performance

Shares of NYSE PHR opened at $8.33 on Tuesday. The business’s 50-day simple moving average is $12.36 and its 200-day simple moving average is $17.57. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. Phreesia has a 52 week low of $7.77 and a 52 week high of $32.76. The firm has a market cap of $502.28 million, a price-to-earnings ratio of 277.70 and a beta of 0.67.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.05). The company had revenue of $127.07 million during the quarter, compared to analyst estimates of $126.75 million. Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.11) earnings per share. As a group, equities research analysts expect that Phreesia will post -1.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Phreesia news, General Counsel Allison C. Hoffman sold 6,176 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $11.97, for a total value of $73,926.72. Following the completion of the sale, the general counsel directly owned 163,485 shares of the company’s stock, valued at $1,956,915.45. This represents a 3.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Amy Beth Vanduyn sold 2,202 shares of the firm’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $36,024.72. Following the completion of the sale, the senior vice president owned 157,349 shares in the company, valued at $2,574,229.64. This represents a 1.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 70,358 shares of company stock valued at $1,123,569 in the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Phreesia

A number of institutional investors have recently added to or reduced their stakes in PHR. Federated Hermes Inc. bought a new position in Phreesia during the third quarter valued at about $32,000. Asset Management One Co. Ltd. acquired a new position in Phreesia in the 3rd quarter valued at approximately $45,000. Van ECK Associates Corp lifted its position in shares of Phreesia by 78.7% in the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after acquiring an additional 1,102 shares during the period. Rockefeller Capital Management L.P. grew its holdings in shares of Phreesia by 354.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock worth $47,000 after purchasing an additional 2,149 shares in the last quarter. Finally, KBC Group NV grew its holdings in shares of Phreesia by 83.4% during the 4th quarter. KBC Group NV now owns 3,449 shares of the company’s stock worth $58,000 after purchasing an additional 1,568 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia News Roundup

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Quarter results showed revenue growth and improved cash generation, with management flagging free cash flow and adjusted EBITDA milestones reached — evidence the business is profitable and generating cash. Business Wire: Phreesia Announces Fourth-Quarter Fiscal 2026 Results
• Neutral Sentiment: Several firms reaffirmed neutral/hold ratings but cut price targets, reflecting mixed conviction — e.g., JPMorgan (neutral, PT $16 from $24), Robert W. Baird (neutral, PT $10 from $25), Citigroup (neutral, PT $10 from $25), and Truist (hold, PT $11 from $24). These actions compress near-term upside expectations even where conviction remains. Benzinga: Why Is Phreesia Stock Sinking Tuesday?
• Negative Sentiment: Management cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the selloff and for multiple analyst downgrades/price-target reductions. Benzinga: Guidance cut explained
• Negative Sentiment: Major brokers sharply trimmed targets and/or ratings (examples: Stephens cut PT to $20 but kept overweight; BMO to $14/outperform; Canaccord to $22/buy; Needham to $14/buy), increasing near-term downside pressure despite some upbeat long-term views. Benzinga: Analyst price target updates
• Negative Sentiment: Market reaction: shares plunged and hit fresh lows on the guidance cut with unusually high volume, signaling broad investor de-risking and driving further volatility. MarketWatch: Shares touch all-time lows

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.